Physician profile
Mark J Dougherty
NPI 1326049628
$11,527.43
in general payments reported to CMS, 2019-2025
30 companies · $2,382 in 2025
The $2,382 reported for 2025 was more than what 87% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,597 · 2020: $367 · 2021: $1,007 · 2022: $1,560 · 2023: $2,592 · 2024: $2,021 · 2025: $2,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,827 · Education: $86.25 · Travel and Lodging: $82.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,827.11 |
| Education | $86.25 |
| Travel and Lodging | $82.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,646.80 | 2019-2025 | Veklury, Biktarvy |
| Viiv Healthcare Company | $1,437.55 | 2019-2025 | Dovato, Rukobia, Apretude |
| Shionogi INC | $1,268.62 | 2021-2025 | Fetroja |
| Insmed, INC. | $1,041.12 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $950.10 | 2019-2025 | Dificid, Zerbaxa, Delstrigo |
| Astellas Pharma US INC | $801.84 | 2019-2025 | Cresemba |
| La Jolla Pharmaceutical Company | $614.01 | 2022-2025 | Xerava, Zevtera, Xacduro |
| Melinta Therapeutics, LLC | $561.17 | 2019-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Paratek Pharmaceuticals, INC. | $447.42 | 2021-2025 | Nuzyra |
| Abbvie INC. | $300.69 | 2019-2025 | Dalvance |
| Tetraphase Pharmaceuticals, INC. | $266.66 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $233.91 | 2023-2025 | Vowst |
| Philips North America LLC | $135.46 | 2023 | |
| Stryker Corporation | $118.93 | 2025 | Core |
| Theratechnologies INC. | $88.05 | 2021-2024 | Egrifta Sv, Trogarzo, Egrifta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $79.22 | 2021-2022 | |
| Pfizer INC. | $75.20 | 2022-2024 | |
| Janssen Products, LP | $69.99 | 2022 | |
| Mayne Pharma Commercial LLC | $54.87 | 2019-2022 | |
| Allergan, INC. | $48.07 | 2019 | |
| Ferring Pharmaceuticals INC. | $44.80 | 2025 | Rebyota |
| Cumberland Pharmaceuticals, INC. | $41.38 | 2024-2025 | Vibativ |
| Csl Behring | $33.06 | 2019 | |
| Vyera Pharmaceuticals, LLC | $30.87 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.54 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Urgo Medical North America, LLC | $27.01 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Alexion Pharmaceuticals, INC. | $20.71 | 2021 | |
| Angiodynamics, INC. | $16.46 | 2023 | Angiovac |
| Biomerieux INC | $16.44 | 2025 | Filmarray Torch Module |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.